Version May 2024
| Risk/stage | 5-year disease-specific survival (%) | Time interval to transplant | Additional considerations |
| Low risk DCIS Stage I | 97 to 99 | No wait time necessary* | Hormone receptor negative disease may have a slightly higher risk of recurrence in the first 2 to 3 years. |
| Intermediate risk Stage II | 90 to 99 | 1 to 2 years NED* | Hormone receptor negative disease may have a slightly higher risk of recurrence in the first 2 to 3 years. |
| High risk Stage III | 66 to 97 | 3 to 5 years NED* | Hormone receptor negative disease may have a slightly higher risk of recurrence in the first 2 to 3 years. Inflammatory breast cancer likely has a higher risk of recurrence and worse survival. |
| Prohibitive risk Stage IV | 32 to 38 | Not an SOT candidate |
DCIS: ductal carcinoma in situ; NED: no evidence of disease.
* After completion of all standard treatments. Endocrine therapy does not need to be completed prior to transplant, as this is an oral medication that is fairly well tolerated with few serious side effects and often continues for 5 to 10 years.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
